News

November 13, 2023
IGM Biosciences Announces Third Quarter 2023 Financial Results
– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif. , Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and
Additional Formats
November 7, 2023
IGM Biosciences to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will present at two upcoming investor
Additional Formats
October 3, 2023
IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
MOUNTAIN VIEW, Calif. , Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg , Ph.D. has retired from its Board of Directors, including as
Additional Formats
August 3, 2023
IGM Biosciences Announces Second Quarter 2023 Financial Results
– Continued progress in clinical development across portfolio – – Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif. , Aug. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company
Additional Formats
June 21, 2023
IGM Announces Proposed Public Offering and Concurrent Private Placement
MOUNTAIN VIEW, Calif. , June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in
Additional Formats
June 1, 2023
IGM Biosciences to Present at the Jefferies Healthcare Conference
MOUNTAIN VIEW, Calif. , June 01, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in a fireside chat at
Additional Formats
Displaying 1 - 10 of 22